Phio Pharma's Intasyl Platform Shows Promising Tumor Control Activity In Animal Studies

Phio Pharmaceuticals Corp PHIO announced new preclinical data for the Intasyl platform in tumor settings.
These data were presented today during the AACR Annual Meeting 2021.
Data showed that local intratumoral (IT) delivery with the murine PD-1 targeting Intasyl (mPH-762) inhibits tumor growth in a dose-dependent fashion in PD-1 responsive and refractory animal models, compared to control-treated tumors.
Furthermore, on-target efficacy was supported by the modulation of immune cell populations toward antitumor phenotypes.
The company believes Intasyl mPH-762 can provide strong local immune checkpoint blockade (ICB) without the dose immune-related adverse effects (irAEs) seen with systemic ICB antibody therapy.
Phio is planning to start the first-in-human clinical study of PH-762 as a directly administered drug in patients with advanced melanoma, scheduled to begin by the end of this year.
Local intratumoral administration can mitigate dose-limiting systemic side effects. All Intasyl treatments were well tolerated.
See the AACR poster here.
Price Action: PHIO shares are down 1.8% at $2.69 in the premarket on the last check Monday.